Last reviewed · How we verify
GSK523338
GSK523338 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.
GSK523338 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | GSK523338 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in inflammatory cells, which suppresses the release of pro-inflammatory cytokines and chemokines. This mechanism reduces airway inflammation and mucus production, making it potentially useful in chronic inflammatory airway diseases. The selective PDE4 inhibition aims to provide anti-inflammatory benefits while minimizing systemic side effects associated with broader phosphodiesterase inhibition.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK523338 CI brief — competitive landscape report
- GSK523338 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI